Source: http://regulations.delaware.gov/register/january2017/emergency/20%20DE%20Reg%20513%2001-01-17.htm
Timestamp: 2018-02-20 23:00:43
Document Index: 77271354

Matched Legal Cases: ['§4713', '§4714', '§4713', '§4713', '§4713', '§10119', '§10119', '§4713']

In Re:	EMERGENCY RULE Final Order
PLACING U-47700
WHEREAS, the Secretary of the Delaware Department of State ("Secretary") has been charged by the Delaware legislature with placing substances in Schedule I if the Secretary finds that the substances: (1) have high potential for abuse; and (2) have no accepted medical use in treatment in the United States or lack accepted safety for use in treatment under medical supervision. 16 Del.C. §4713; and
WHEREAS, available data and information for 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) indicate that this synthetic opioid has a high potential for abuse, no currently accepted medical use in treatment in the United States and lacks accepted safety for use under medical supervision; and
WHEREAS, U-47700 is not currently listed in any schedule under Delaware law; and
WHEREAS, U-47700, also known as "Pink," is a synthetic opioid recently encountered by law enforcement and public health officials and is being abused for its opioid properties. It is available over the Internet and is marketed as a "research chemical." The DEA is aware of the identification of U-47700 from toxicology reports and other evidence in a number of states, including New Jersey and Pennsylvania and has received data documenting at least 46 confirmed fatalities associated with the substance. The safety risks to users are significant and the public health risks include large numbers of drug treatment admissions, emergency room visits and fatal overdoses; and
WHEREAS, on November 14, 2016, the Federal Drug Enforcement Agency published in the Federal Register a Final Order, 81 FR 79389 (Nov. 14, 2016), temporarily placing U-47700 in Schedule I for a two-year period, with a possible extension of one additional year, finding that this synthetic opioid has a high potential for abuse, no currently accepted medical use in treatment in the United States and lacks accepted safety for use under medical supervision; and
WHEREAS, the Delaware Controlled Substance Advisory Committee has recommended the enactment of an emergency regulation placing U-47700 in Schedule I; and
WHEREAS, the Secretary finds that adoption of a regulation placing U-47700 temporarily in Schedule I under Delaware law must occur on an emergency basis in order to properly protect the public until such time as the legislature may reconvene to adopt a statutory amendment to 16 Del.C. §4714; and
WHEREAS, the Secretary will accept, consider and respond to petitions by any interested person for the reconsideration or revision of this regulation by addressing the same to the attention of the Office of Controlled Substances, Cannon Building, 861 Silver Lake Blvd., Dover, DE 19904; and
WHEREAS, a copy of this Final Order will be submitted to the Registrar for publication in the next issue of the Delaware Register of Regulations;
NOW, THEREFORE, IT IS ORDERED this 15th day of December, 2016:
1.	The Uniform Controlled Substance Act Regulations are amended as follows:
1.	Following the existing rule 10.2.1, insert a new rule 10.3 as follows:
10.3 Pursuant to 16 Del.C. §4713 the Secretary of State finds that the synthetic opioid, 3, 4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700) and it isomers, esters, ethers, salts and salts of isomers, esters and ethers, has high potential for abuse; has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision, and therefore:
10.3.1 The Secretary of State, as authorized by 16 Del.C. §4713, does hereby add by rule 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700) and it isomers, esters, ethers, salts and salts of isomers, esters and ethers, in Schedule I of the Uniform Controlled Substances Act, 16 Del.C. Ch. 47.
BEFORE THE DELAWARE CONTROLLED SUBSTANCE
In Re:	EMERGENCY RULE Recommendation
Pursuant to due notice, a special meeting of the Delaware Controlled Substance Advisory Committee ("Committee") was held on December 9, 2016 concerning the synthetic opioid, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as "U-47700").
The Committee reviewed the Federal Drug Enforcement Administration ("DEA") Final Order temporarily placing U-47700, and its isomers, esters, ethers, salts and salts of isomers, esters and ethers, into Schedule I. 81 FR 79389 (Nov. 14, 2016).
16 Del.C. §4713 establishes that "[t]he Secretary [of State] shall place a substance in Schedule I if the Secretary finds that the substance: (1) Has high potential for abuse; and (2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision." Further, emergency regulations may be promulgated pursuant to the Administrative Procedures Act, so long as an agency determines there exists "an imminent peril to the public health, safety or welfare." 29 Del.C. §10119. Such a regulation will only be effective for a maximum of 120 days, but may be renewed once for an additional period of sixty days. 29 Del.C. §10119(3). The Uniform Controlled Substance Act Regulations also directly address the adoption of emergency regulations. Specifically, the regulations state at Section 9.3:
If the Secretary of State, upon the recommendation of the Committee, finds that an imminent peril to the public health, safety or welfare requires adoption of a regulation upon fewer than twenty (20) days notice and states in writing his/her reasons for that finding, the Secretary of State may proceed without prior notice or hearing or upon any abbreviated notice and hearing he/she finds practicable, to adopt an emergency regulation. Such rules will be effective for a period not longer than 120 days, but the adoption of an identical rule under the procedures discussed above is not precluded.
U-47700, also known as "Pink," is a synthetic opioid recently encountered by law enforcement and public health officials. Scientific literature shows that U-47700 is being abused for its opioid properties. It is available over the Internet and is marketed as a "research chemical." The DEA is aware of the identification of U-47700 from toxicology reports and other evidence in a number of states, including New Jersey and Pennsylvania. Further, the DEA has received data documenting at least 46 confirmed fatalities associated with U-47700. The abuse of U-47700 leads to the same public health risks as heroin, fentanyl and other opioid analgesic substances. The safety risks to users are significant and the public health risks include large numbers of drug treatment admissions, emergency room visits and fatal overdoses. The DEA concluded that U-47700 has a high potential for abuse, no currently accepted medical use in treatment in the United States and a lack of accepted safety for use under medical supervision. The DEA consequently issued a Final Order temporarily placing U-47700 in Schedule I.
For the reasons set forth in the DEA Final Order published November 14, 2016, the Committee finds that allowing the synthetic opioid U-47700 to remain unscheduled in the State of Delaware presents an imminent peril to the public health, safety and welfare. The Committee therefore recommends that U-47700 be added to Schedule I of the Delaware Uniform Controlled Substances Act.
In order to protect the public and address the peril posed by U-47700, the Committee recommends an emergency regulation be adopted in a manner as follows:
Following the existing rule 10.2.1, insert a new rule 10.3 as follows:
IT IS SO RECOMMENDED this 9th day of December 2016.
BY THE DELAWARE CONTROLLED SUBSTANCE ADVISORY COMMITTEE
Herb E. Von Goerres
Art Jankowski (absent)
Luis Garcia (absent)
Philip Kim (absent)
Alex Zarrow (absent)
10.3	Pursuant to 16 Del.C. §4713 the Secretary of State finds that the synthetic opioid, 3, 4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700) and it isomers, esters, ethers, salts and salts of isomers, esters and ethers, has high potential for abuse; has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision, and therefore:
20 DE Reg. 513 (01/01/17) (Emer.)